Earnings summaries and quarterly performance for ALLURION TECHNOLOGIES.
Executive leadership at ALLURION TECHNOLOGIES.
Board of directors at ALLURION TECHNOLOGIES.
Research analysts who have asked questions during ALLURION TECHNOLOGIES earnings calls.
JJ
Joshua Jennings
TD Cowen
6 questions for ALUR
Also covers: ABT, ATEC, BDX +22 more
JW
Jason Wittes
Roth Capital Partners, LLC
3 questions for ALUR
Also covers: ARAY, ATEC, CV +13 more
KN
Keay Nakae
Chardan Capital Markets
3 questions for ALUR
Also covers: STEM, SYBX
MT
Mike Tomey
Jefferies
2 questions for ALUR
MT
Matthew Taylor
Jefferies
1 question for ALUR
Also covers: BDX, BSX, CQP +21 more
Michael Toomey
Jefferies
1 question for ALUR
Also covers: ICUI
Recent press releases and 8-K filings for ALUR.
Allurion Technologies Receives NYSE Delisting Notice
ALUR
Delisting/Listing Issues
Legal Proceedings
- Allurion Technologies, Inc. (ALUR) received a notice from the New York Stock Exchange (NYSE) on March 2, 2026, initiating delisting proceedings due to non-compliance with listing standards requiring $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis.
- The company intends to appeal this determination, and its common stock is expected to continue trading on the NYSE during the appeal process.
- Allurion's plan to regain compliance or relist includes ongoing discussions with creditors and security holders, capital raising efforts, and is catalyzed by a recent FDA approval on February 20, 2026.
- There is no guarantee that the appeal will be successful, or that the company will regain compliance with NYSE standards or be able to relist on another exchange.
Mar 2, 2026, 2:18 PM
Allurion Technologies, Inc. Announces Warrant Exercise Inducement Offer
ALUR
- Allurion Technologies, Inc. (ALUR) launched an inducement offer for holders of its January 2025, February 2025, and November 2025 warrants to exercise them for cash.
- The exercise price for these existing warrants was reduced to $1.15 per share, and the company expects to receive approximately $3.0 million in aggregate gross proceeds from the exercise of 2,659,565 shares of Common Stock by exercising holders.
- As part of the inducement, exercising holders will receive new unregistered common stock purchase warrants to acquire up to 5,319,130 additional shares of Common Stock, also exercisable at $1.15 per share after stockholder approval, with a five-year term.
Feb 25, 2026, 1:30 PM
Allurion Technologies Announces Preliminary Q4 and Full-Year 2025 Results
ALUR
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Allurion Technologies announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
- Fourth-quarter revenue is estimated to be between $3.3 million and $3.7 million, representing a 22% to 37% increase quarter-over-quarter.
- Full-year 2025 revenue is approximately $15 million.
- The company reported substantial improvement in operating expenses and operating loss quarter-over-quarter and compared to the prior year.
- Management stated that this was the first quarter-over-quarter revenue growth in over a year and anticipates a potential FDA approval of the Allurion Smart Capsule in 2026.
Jan 12, 2026, 9:30 PM
Allurion Technologies Reports Q3 2025 Results and Provides FDA Update
ALUR
Earnings
New Projects/Investments
Convertible Preferred Issuance
- Allurion Technologies reported Q3 2025 revenue of $2.7 million, a decrease from $5.4 million in Q3 2024, primarily due to a restructuring.
- The company significantly narrowed its operating losses, with operating loss at $9.6 million (down 22% year-over-year) and adjusted net operating loss at $6.9 million (down 39% year-over-year).
- Allurion is advancing towards FDA approval for the Smart Capsule, having passed pre-approval and BIMO inspections with no observations and completing the Day 100 meeting without requests for additional human clinical data.
- A strategic pivot involves focusing on accounts that combine the Allurion program with low-dose GLP-1s, anticipating long-term growth from GLP-1 discontinuation patients.
- The company is restructuring its balance sheet to become debt-free through a convertible preferred equity exchange and a $5 million private placement financing.
Nov 12, 2025, 1:30 PM
Allurion Technologies Reports Q3 2025 Results and Key FDA Milestones
ALUR
Earnings
Convertible Preferred Issuance
New Projects/Investments
- Allurion Technologies successfully passed FDA Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and completed the Day-100 meeting for the Allurion Smart Capsule, indicating entry into the final stages of the Premarket Approval (PMA) process.
- The company is strengthening its balance sheet by entering into a transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced a $5 million private placement financing.
- For the third quarter ended September 30, 2025, total revenue was $2.7 million, a decrease from $5.4 million in the same period of 2024. The operating loss was $9.6 million, reduced from $12.3 million in Q3 2024, with an adjusted operating loss of $6.9 million.
- As of September 30, 2025, cash and cash equivalents were $6.1 million, not including the $5 million from the private placement financing.
Nov 12, 2025, 1:15 PM
Quarterly earnings call transcripts for ALLURION TECHNOLOGIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more